{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":20,"n_cols":5,"rows_kept":20,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[12,2,12,3],[16,2,16,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9911019238103321"]
[null,null,"Autore",null,"Foundation Novartis"]
[null,null,"Titolo",null,"Drug resistance in epilepsy"]
[null,null,"Pubbl/distr/stampa",null,"New York : , : Wiley, , 2003"]
[{"$nulls":4},"©2003"]
[null,null,"ISBN",null,"0-470-84635-6"]
[{"$nulls":4},"9786610554881"]
[{"$nulls":4},"1-280-55488-6"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (254 pages)"]
[null,null,"Collana",null,"Novartis Foundation Symposia ; ; v.Vol. 243"]
[null,null,"Disciplina",null,"616.853061"]
[null,null,"Soggetti",null,"Epilepsy - drug therapy"]
[{"$nulls":4},"ATP Binding Cassette Transporter, Subfamily B - metabolism"]
[{"$nulls":4},"Drug Resistance"]
[{"$nulls":4},"Congress."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Sommario/riassunto","The object of this book is to gather together workers in the fields of epilepsy, those concerned with the basic science of resistance and the blood-brain barrier, and those with clinical experience of drug resistance in cancer, with a view to stimulating further work on drug resistance in epilepsy. Whilst resistance in cancer has been extensively studied, and trials of reversal of resistance have been undertaken, with some success, resistance in epilepsy has only just begun to be addressed."]